Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRASOL
NL-OMON55302Phase 3Active, not recruiting
- Sponsor
- ImmunoGen
- Start
- Jun 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by ImmunoGen. Primary endpoint: Progression-free survival. Started Jun 2021; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON55302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55302.